Trump: No, we’re looking for a full vaccine for everyone that wants to get it. Not everybody is going to want to get it.
https://www.whitehouse.gov/briefings-statements/remarks-president-trump-vaccine-development/
This is the REAL news that was announced today:
Who is the New Leader of Operation Warp Speed?
President Trump announced that Moroccan-born Dr. Moncef Slaoui, the former chairman of GlaxoSmithKline’s vaccines division, would serve as Chief Adviser for Operation Warp Speed, the administration’s project to fast-track a COVID-19 vaccine.
Slaoui will work together with General Gustave Perna, who was appointed as the Chief Operation Officer for Operation Warp Speed.
Dr. Slaoui will become yet another member of President Trump’s medical advisors with strong ties to Bill Gates. During his days as chairman of GlaxoSmithKline’s vaccines division, Slaoui was instrumental in developing the vaccine Mosquirix, a malaria vaccine for use in tropical and subtropical areas. (Source.)
The drug was funded through The Bill and Melinda Gates Foundation.
In an article published on the website The Borgen Project, titled Mosquirix: New Malaria Vaccine Approved, author Katie Pickle stated in 2015 that:
Thanks to the efforts of GlaxoSmithKline and the generous support of The Bill and Melinda Gates Foundation, the world’s first malaria vaccine has been approved by regulators at the European Medicine Agency.
GSK worked with the PATH Malaria Vaccine Initiative to create the immunization, which is meant for use in tropical and subtropical areas where the illness is prevalent and largely uncontrolled. Called RTS,S in its experimental stages, Mosquirix is designed for children 6-17 months old whose immune systems are still developing.
The Bill and Melinda Gates Foundation contributed over $200 million to the drug’s research and development, and GSK is optimistic that it will be effective in reducing incidences of malaria in Sub-Saharan Africa where cases of malaria caused by the parasite are most common.
The vaccine is not without its short-comings, as Pickle reported:
The main road bump for Mosquirix? Distribution. The vaccine may exist, but to the young children in Africa who need it, it may as well be a fantasy.
The question is whether the distribution of the vaccination to areas where it is needed is worth the time and the money. The World Health Organization is skeptical of the feasibility of Mosquirix’s implementation and has not yet issued a recommendation for its use.
There is a reason that most vaccines are not made against parasites – unlike bacteria or a virus, a parasite has a complicated life cycle that transports it around the body. Parasites like those that cause malaria can remain living in the body for years.
Almost 5 years later now, the World Health Organization has approved the use of Mosquirix in African countries, but the problems remain. A report in JSTOR Daily last month (April 2020) states:
After 30 years of work, the first malaria vaccine was rolled out in Africa in 2019, despite concerns about it efficiency and safety. Named Mosquirix, it works by stimulating an immune response against a protein found on the sporozoites’ surface. Set up by WHO, the pilot effort aimed to vaccinate hundreds of thousands of children in Malawi, Ghana, and Kenya.
Since leaving his position as the chairman of the vaccine division at GSK, Dr. Slaoui has taken on roles at several other biotech medical firms, usually sitting on their board of directors.
Government watchdog groups were quick to point out the obvious conflicts of interest with Dr. Slaoui receiving funds to develop a COVID-19 vaccine, including sitting on the board with the same pharmaceutical company working with Dr. Anthony Fauci that has received hundreds of billions of dollars to develop a COVID-19 vaccine, Moderna, Inc.
Common Dreams Staff Writer Julia Conley writes:
Government watchdog Public Citizen on Thursday condemned the Trump administration’s reported appointment of a former pharmaceutical executive to the White House’s task force aimed at swiftly developing a Covid-19 vaccine…
The administration named Moncef Slaoui, former head of GlaxoSmithKline’s vaccine division and a venture capitalist in the pharmaceutical field, to act as chief adviser for the program, called “Operation Warp Speed.”
Slaoui worked at GlaxoSmithKline for 30 years until 2017, and since then has sat on the boards of a number of pharmaceutical firms which are now researching potential vaccines for the coronavirus—leaving the former executive with what Public Citizen called “blatant financial conflicts of interest.”
Currently a partner at pharmaceutical investment firm Medicxi, Slaoui has earned $490,000 as a board member at Moderna, Inc. and also sits on the board of Lonza Group AG, a Swiss company which is contracting with Moderna to find a Covid-19 vaccine. His former employer, GlaxoSmithKine, is also working to develop an immunization.
Dr. Slaoui also has ties to Alphabet, the parent company of Google.
As a partner at Medicxi, a venture capital group that invests in pharmaceutical industry companies, he sits on the board of several companies that Medicxi has invested in, including serving as chairman of the board at Galvani Bioelectronics, a company formed in 2016 with funding from GSK and Google. (Source.)
As we have previously reported here at Health Impact News, Google is now a pharmaceutical company, and a major player in the biotech industry, which may explain why they suppress anything negative regarding vaccines in their search results.
Galvani Bioelectronics is dedicated to the development of bioelectronic medicines – a new class of medicines consisting of miniaturised, implantable devices. (Source.)
While serving as chairman of the vaccine division of GSK, Dr. Slaoui helped develop several highly profitable vaccines, including:
• Rotarix®, to prevent infantile rotavirus gastroenteritis
• Synflorix®, to prevent pneumococcal disease
• Mosquirix, to prevent plasmodium malaria disease
• Shingrix, to prevent shingles
• Cervarix®, an HPV vaccine to prevent cervical cancer
Cervarix is GSK’s equivalent to Merck’s Gardasil HPV vaccine, which has been linked to serious injuries to young girls, including infertility.
Dr. Moncef Slaoui also sits on the board of the International AIDS Vaccine Initiative. (Source.)
As we have previously reported, especially through the investigative work of Robert F. Kennedy, Jr., Chairman of the Children’s Health Defense, Bill Gates, Dr. Anthony Fauci, Dr. Deborah Birx, and CDC Director Robert Redfield all have a long history of working together on trying to develop an HIV/AIDS vaccine.
And now we can add Dr. Moncef Slaoui to this team, all being employed by the U.S. Federal Government (except for Bill Gates who does not need to be employed by anyone) to fast-track the COVID-19 vaccine, that President Trump just announced will be deployed by the U.S. military.
Source.
